The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Seres Therapeutics Inc (NASDAQ: MCRB) closed at $0.73 down -4.74% from its previous closing price of $0.77. In other words, the price has decreased by -$4.74 from its previous closing price. On the day, 1.21 million shares were traded. MCRB stock price reached its highest trading level at $0.7687 during the session, while it also had its lowest trading level at $0.7206.
Ratios:
For a deeper understanding of Seres Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 3.91 whereas as Long-Term Debt/Eq ratio is at 3.56.
On April 21, 2023, JP Morgan started tracking the stock assigning a Neutral rating and target price of $7.JP Morgan initiated its Neutral rating on April 21, 2023, with a $7 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 18 ’24 when DesRosier Thomas sold 878 shares for $0.54 per share. The transaction valued at 475 led to the insider holds 135,192 shares of the business.
von Moltke Lisa sold 977 shares of MCRB for $528 on Nov 18 ’24. The insider now owns 32,415 shares after completing the transaction at $0.54 per share. On Nov 18 ’24, another insider, Shaff Eric D., who serves as the CEO and President of the company, sold 2,505 shares for $0.54 each. As a result, the insider received 1,355 and left with 170,389 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MCRB now has a Market Capitalization of 124809480 and an Enterprise Value of 125503312. For the stock, the TTM Price-to-Sale (P/S) ratio is 2080.09 while its Price-to-Book (P/B) ratio in mrq is 5.20. Its current Enterprise Value per Revenue stands at 0.993 whereas that against EBITDA is -3.439.
Stock Price History:
The Beta on a monthly basis for MCRB is 2.10, which has changed by -0.33304346 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, MCRB has reached a high of $1.53, while it has fallen to a 52-week low of $0.54. The 50-Day Moving Average of the stock is -10.61%, while the 200-Day Moving Average is calculated to be -17.41%.
Shares Statistics:
For the past three months, MCRB has traded an average of 2.64M shares per day and 2212060 over the past ten days. A total of 170.20M shares are outstanding, with a floating share count of 124.81M. Insiders hold about 26.90% of the company’s shares, while institutions hold 23.57% stake in the company. Shares short for MCRB as of 1735603200 were 20440169 with a Short Ratio of 7.74, compared to 1732838400 on 17381399. Therefore, it implies a Short% of Shares Outstanding of 20440169 and a Short% of Float of 16.02.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.12 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.11 and -$0.94 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.41, with 4.0 analysts recommending between -$0.02 and -$0.82.
